Xin Liu

Dr. Xin Liu

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2021 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
NNNhung Thi Nguyen
Nhung Thi Nguyen
KHKai Huang
Kai Huang
HZHongxiang Zeng
Hongxiang Zeng
JJJi Jing
Ji Jing
RWRui Wang
Rui Wang
Yubin ZhouYubin Zhou
Yubin Zhou

1 August 2016 in Cell Reports
Verified
Journal Article
Open access
TLTao Liu
Tao Liu
QTQin Tang
Qin Tang
KLKunpeng Liu
Kunpeng Liu
WXWeihong Xie
Weihong Xie
XLXin Liu
Xin Liu
JCJun Cui
Jun Cui
The AIM2 inflammasome is a key cytosolic signaling complex that is activated by double-stranded DNA, leading to the maturation of proinflammatory cytokines such as interleukin-1β (IL-1β) and IL-18. Dysregulated AIM2 inflammasome activity is associated with human inflammatory diseases and cancers, suggesting that its activity must be tightly regulated. However, the precise molecular mechanisms that control AIM2 levels and activity are still poorly understood. Here, we report tripartite motif 11 (TRIM11) as a key negative regulator of the AIM2 inflammasome. Upon DNA virus infection, TRIM11 binds to AIM2 via its PS domain and undergoes auto-polyubiquitination at K458 to promote an association between TRIM11 and the autophagic cargo receptor p62 to mediate AIM2 degradation via selective autophagy. These findings identify a role for TRIMs in AIM2 inflammasome activation where TRIM11 acts as a secondary receptor to deliver AIM2 to the autophagosomes for degradation in a p62-dependent manner.

27 September 2021 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
JCJunjun Chu
Junjun Chu
CXChangsheng Xing
Changsheng Xing
YDYang Du
Yang Du
TDTianhao Duan
Tianhao Duan
SLSiyao Liu
Siyao Liu
RWRongfu Wang
Rongfu Wang

21 March 2024 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
TDTianhao Duan
Tianhao Duan
CXChangsheng Xing
Changsheng Xing
JCJunjun Chu
Junjun Chu
XDXiangxue Deng
Xiangxue Deng
YDYang Du
Yang Du
RWRongfu Wang
Rongfu Wang

28 April 2023 in Genes
Verified
Journal Article
Open access
PDF file
CCChristina Chen
Christina Chen
XLXin Liu
Xin Liu
CCChe-Yu Chang
Che-Yu Chang
HWHelen Y. Wang
Helen Y. Wang
RWRongfu Wang
Rongfu Wang
Over the past decade, immunotherapy has emerged as one of the most promising approaches to cancer treatment. The use of immune checkpoint inhibitors has resulted in impressive and durable clinical responses in the treatment of various cancers. Additionally, immunotherapy utilizing chimeric antigen receptor (CAR)-engineered T cells has produced robust responses in blood cancers, and T cell receptor (TCR)-engineered T cells are showing promising results in the treatment of solid cancers. Despite these noteworthy advancements in cancer immunotherapy, numerous challenges remain. Some patient populations are unresponsive to immune checkpoint inhibitor therapy, and CAR T cell therapy has yet to show efficacy against solid cancers. In this review, we first discuss the significant role that T cells play in the body’s defense against cancer. We then delve into the mechanisms behind the current challenges facing immunotherapy, starting with T cell exhaustion due to immune checkpoint upregulation and changes in the transcriptional and epigenetic landscapes of dysfunctional T cells. We then discuss cancer-cell-intrinsic characteristics, including molecular alterations in cancer cells and the immunosuppressive nature of the tumor microenvironment (TME), which collectively facilitate tumor cell proliferation, survival, metastasis, and immune evasion. Finally, we examine recent advancements in cancer immunotherapy, with a specific emphasis on T-cell-based treatments.

16 November 2023 in EMBO Reports
Verified
Journal Article
Open access
TDTianhao Duan
Tianhao Duan
YFYanchun Feng
Yanchun Feng
YDYang Du
Yang Du
CXChangsheng Xing
Changsheng Xing
JCJunjun Chu
Junjun Chu
RWRongfu Wang
Rongfu Wang
Microbial products, such as lipopolysaccharide (LPS), can elicit efficient innate immune responses against invading pathogens. However, priming with LPS can induce a form of innate immune memory, termed innate immune "tolerance", which blunts subsequent NF-κB signaling. Although epigenetic and transcriptional reprogramming has been shown to play a role in innate immune memory, the involvement of post-translational regulation remains unclear. Here, we report that ubiquitin-specific protease 3 (USP3) participates in establishing "tolerance" innate immune memory through non-transcriptional feedback. Upon NF-κB signaling activation, USP3 is stabilized and exits the nucleus. The cytoplasmic USP3 specifically removes the K63-linked polyubiquitin chains on MyD88, thus negatively regulating TLR/IL1β-induced inflammatory signaling activation. Importantly, cytoplasmic translocation is a prerequisite step for USP3 to deubiquitinate MyD88. Additionally, LPS priming could induce cytoplasmic retention and faster and stronger cytoplasmic translocation of USP3, enabling it to quickly shut down NF-κB signaling upon the second LPS challenge. This work identifies a previously unrecognized post-translational feedback loop in the MyD88-USP3 axis, which is critical for inducing normal "tolerance" innate immune memory.